Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MLTX - KY61559X1045 - Common Stock

18.49 USD
+4.15 (+28.94%)
Last: 1/9/2026, 8:00:01 PM
19.3007 USD
+0.81 (+4.38%)
After Hours: 1/9/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, MLTX scores 2 out of 10 in our fundamental rating. MLTX was compared to 530 industry peers in the Biotechnology industry. MLTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MLTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MLTX had negative earnings in the past year.
MLTX had a negative operating cash flow in the past year.
MLTX had negative earnings in each of the past 5 years.
In the past 5 years MLTX always reported negative operating cash flow.
MLTX Yearly Net Income VS EBIT VS OCF VS FCFMLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

MLTX has a Return On Assets of -50.80%. This is comparable to the rest of the industry: MLTX outperforms 49.43% of its industry peers.
MLTX has a Return On Equity (-72.86%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.8%
ROE -72.86%
ROIC N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLTX Yearly ROA, ROE, ROICMLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

MLTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLTX Yearly Profit, Operating, Gross MarginsMLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MLTX has more shares outstanding
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLTX Yearly Shares OutstandingMLTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
MLTX Yearly Total Debt VS Total AssetsMLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.80 indicates that MLTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of MLTX (2.80) is better than 68.11% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that MLTX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, MLTX is doing worse than 66.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 2.8
ROIC/WACCN/A
WACCN/A
MLTX Yearly LT Debt VS Equity VS FCFMLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.50 indicates that MLTX has no problem at all paying its short term obligations.
MLTX has a better Current ratio (8.50) than 76.23% of its industry peers.
A Quick Ratio of 8.50 indicates that MLTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.50, MLTX is in the better half of the industry, outperforming 76.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.5
Quick Ratio 8.5
MLTX Yearly Current Assets VS Current LiabilitesMLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MLTX have decreased strongly by -157.36% in the last year.
EPS 1Y (TTM)-157.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.92% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.21%
EPS Next 2Y-38.62%
EPS Next 3Y-22.72%
EPS Next 5Y5.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLTX Yearly Revenue VS EstimatesMLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
MLTX Yearly EPS VS EstimatesMLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Also next year MLTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLTX Price Earnings VS Forward Price EarningsMLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLTX Per share dataMLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as MLTX's earnings are expected to decrease with -22.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.62%
EPS Next 3Y-22.72%

More info and screens

0

5. Dividend

5.1 Amount

MLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (1/9/2026, 8:00:01 PM)

After market: 19.3007 +0.81 (+4.38%)

18.49

+4.15 (+28.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-24 2026-02-24/bmo
Inst Owners60.93%
Inst Owner Change0%
Ins Owners9.99%
Ins Owner Change-8.39%
Market Cap1.33B
Revenue(TTM)N/A
Net Income(TTM)-210.50M
Analysts87.5
Price Target19.22 (3.95%)
Short Float %7.6%
Short Ratio2.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.5%
Min EPS beat(2)-22.75%
Max EPS beat(2)-18.26%
EPS beat(4)1
Avg EPS beat(4)-10.31%
Min EPS beat(4)-22.75%
Max EPS beat(4)17.89%
EPS beat(8)2
Avg EPS beat(8)-8.49%
EPS beat(12)6
Avg EPS beat(12)0.35%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.21%
PT rev (3m)-76.13%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-11.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.6
P/tB 4.6
EV/EBITDA N/A
EPS(TTM)-3.32
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-2.59
FCFYN/A
OCF(TTM)-2.58
OCFYN/A
SpS0
BVpS4.02
TBVpS4.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.8%
ROE -72.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.5
Quick Ratio 8.5
Altman-Z 2.8
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)797.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-157.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
EPS Next Y-92.21%
EPS Next 2Y-38.62%
EPS Next 3Y-22.72%
EPS Next 5Y5.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-111.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.13%
EBIT Next 3Y-28.27%
EBIT Next 5YN/A
FCF growth 1Y-342.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-341.9%
OCF growth 3YN/A
OCF growth 5YN/A

MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ

Can you provide the ChartMill fundamental rating for MOONLAKE IMMUNOTHERAPEUTICS?

ChartMill assigns a fundamental rating of 2 / 10 to MLTX.


Can you provide the valuation status for MOONLAKE IMMUNOTHERAPEUTICS?

ChartMill assigns a valuation rating of 0 / 10 to MOONLAKE IMMUNOTHERAPEUTICS (MLTX). This can be considered as Overvalued.


How profitable is MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a profitability rating of 1 / 10.


How financially healthy is MOONLAKE IMMUNOTHERAPEUTICS?

The financial health rating of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 5 / 10.